Biodigital convergence nano biotechnology ethylene oxide hydrogel nasal swab face masks biological computers
And the conspiracy continues the dangers of ethylene oxide
Hey man get your nasal swab false PCR test done….. hey man put your face mask on take a couple deep breaths everything will be okay…. In the day and age of self-assembling and self replicating all they need is a little dab I mean a little dab.. both nasal swab and face mask contain ethylene oxide.. and the jabs contain polyethylene glycol which is the quantum dot, and contain hydrogel.. This article is about computers composed of biological parts. (Not necessarily the ones that are in the nasal swabs or the face mask or the jabs but for educational purposes) For computation inspired by biology, see Bio-inspired computing. For hypothetical computers using brain-to-brain interfaces, see Brain–brain interface. For the analysis of computation in natural organisms, see Biological computation.
AND THE BIODIGITAL CONVERGENCE CONTINUES
What's in your nasal swab for testing? https://forbiddenknowledgetv.net/certified-federal-medical-investigator-gives-terrifying-info-about-covid-testing-swabs/ ethylene oxide
https://pubmed.ncbi.nlm.nih.gov/?term=Ethylene+oxide
The major use of ethylene oxide is as a chemical intermediate in the manufacture of ethylene glycol.
Ethylene oxide is also used as a sterilizing agent for medical equipment and a fumigating agent for
spices. The acute (short-term) effects of ethylene oxide in humans consist mainly of central nervous
system depression and irritation of the eyes and mucous membranes. Chronic (long-term) exposure to
ethylene oxide in humans can cause irritation of the eyes, skin, nose, throat, and lungs, and damage to
the brain and nervous system. There also is some evidence linking ethylene oxide exposure to
reproductive effects. EPA has concluded that ethylene oxide is carcinogenic to humans by the inhalation
route of exposure. Evidence in humans indicates that exposure to ethylene oxide increases the risk of
lymphoid cancer and, for females, breast cancer https://www.epa.gov/sites/default/files/2016-09/documents/ethylene-oxide.pdf
ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins
Hydrogels are very attractive delivery systems for hydrophilic macromolecules such as proteins and DNA because they provide a protective environment and allow control of diffusion by adjusting cross-link densities. Physically cross-linked hydrogels generated by rapid swelling upon exposure to an aqueous environment can be obtained from ABA triblock copolymers containing hydrophobic polyester A-blocks and hydrophilic polyether B-blocks. They provide an attractive alternative to chemically cross-linked systems since they allow incorporation of macromolecular drug substances under mild process conditions. Moreover, they show controlled degradation behavior and excellent biocompatibility. In this review the synthesis and characterization of ABA triblock copolymers from polyester hard segments and poly(ethylene oxide) [PEO] soft segments as well as their biological and degradation properties https://pubmed.ncbi.nlm.nih.gov/11755708/
Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion?
Erosion of biodegradable parenteral delivery systems (PDS) based on ABA copolymers consisting of poly(L-lactide-co-glycolide) (PLGA) A-blocks attached to polyethylene oxide (PEO) B-blocks, or PLGA is important for the release of macromolecular drugs. The degradation behavior of four types of PDS, namely extruded rods, tablets, films and microspheres, was studied with respect to molecular weight, mass, polymer composition and shape and microstructure of the PDS. https://pubmed.ncbi.nlm.nih.gov/11343880/ Double hydrophilic block copolymers self-assemblies in biomedical applications (DHBCs) Double-hydrophilic block copolymers , consisting of at least two different water-soluble blocks, are an alternative to the classical amphiphilic block copolymers and have gained increasing attention in the field of biomedical applications. Although the chemical nature of the two blocks can be diverse, most classical DHBCs consist of a bioeliminable non-ionic block to promote solubilization in water, like poly(ethylene glycol), pollyethylene glycol is where the quantum dot's come from or carbon dots here's a hole list
https://pubmed.ncbi.nlm.nih.gov/?term=Polyethylene+glycol+quantum+dots+
https://pubmed.ncbi.nlm.nih.gov/?term=Polyethylene+glycol+carbon+dots
A second block that is more generally a pH-responsive block capable of interacting with another ionic polymer or substrate. https://www.sciencedirect.com/science/article/abs/pii/S0001868620301706
Preparation of Quantum Dots Hydrogel Nanocomposites with Improved Cytotoxicity
Nanocomposites are materials with unique properties and a wide range of applications. The combination of different nanostructures with traditional materials gives a variety of possibilities that should be analyzed. Especially, functional fluorescent semiconductor quantum dots (QDs) embedded in polymeric matrices have shown promising fluorescence and biocompatibility properties. These hybrid materials can be used in medical applications such as biodiagnostic and bioimaging https://pubmed.ncbi.nlm.nih.gov/29648418/
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review
Lipid-polymer hybrid nanoparticles (LPNs) are core-shell nanoparticle structures comprising polymer cores and lipid/lipid-PEG shells, which exhibit complementary characteristics of both polymeric nanoparticles and liposomes, particularly in terms of their physical stability and biocompatibility. Significantly, the LPNs have recently been demonstrated to exhibit superior in vivo cellular delivery efficacy compared to that obtained from polymeric nanoparticles and liposomes. Since their inception, the LPNs have advanced significantly in terms of their preparation strategy and scope of applications. Their preparation strategy has undergone a shift from the conceptually simple two-step method, involving preformed polymeric nanoparticles and lipid vesicles, to the more principally complex, yet easier to perform, one-step method, relying on simultaneous self-assembly of the lipid and polymer https://open.substack.com/pub/operationsavehumanity/p/5268-hydrogels-including-the-stretchable?r=24qa7g&utm_campaign=post&utm_medium=web https://open.substack.com/pub/operationsavehumanity/p/total-exposure-lipidsnano-particles?r=24qa7g&utm_campaign=post&utm_medium=web https://open.substack.com/pub/operationsavehumanity/p/remind-you-of-anything?r=24qa7g&utm_campaign=post&utm_medium=web
Traveler-based Genomic Surveillance for Early Detection of New SARS-CoV-2 Variants
The Traveler-based Genomic Surveillance program (TGS), led by CDC’s Travelers’ Health Branch, is a public-private partnership that plays an important role in U.S. national biosecurity through its two major goals:
early detection of new SARS-CoV-2 variants and other pathogens and
filling in gaps in global biosurveillance.
Well what do they need bio surveillance for? Well who's doing that ?
Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens
BOSTON, Nov. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and XWELL, Inc. (Nasdaq: XWEL) today announced they are expanding their work with the U.S. Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program (TGS) to test for more than 30 additional priority pathogens, in addition to SARS-CoV https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-xwell-implement-expanded-cdc-traveler-based-genomic-surveillance-program-to-test-for-more-than-30-known-pathogens-301977874.html
Enzyme Engineering and Artificial Intelligence But we’re entering a new era–one in which we can train Artificial Intelligence (AI) models based on large biological data sets. This is where Ginkgo Bioworks comes in. Our expansive cell engineering platform is a data-generating powerhouse, churning out the kind of high-quality, voluminous data that AI algorithms thrive on. The marriage of this large-scale data generation with AI models allows us to transcend previous limitations, making Ginkgo an ideal environment to train and deploy machine learning tools for the complex art of enzyme engineering https://www.ginkgobioworks.com/2022/10/18/ag-biologics-division-bayer-joyn/
Thomas Kurian, CEO of Google Cloud, put it like this: “Our strategic partnership with Ginkgo is a first-of-its-kind for Google Cloud, underscoring our confidence that Ginkgo will play a critical and pioneering role in the life sciences space, leveraging AI to reshape humanity’s understanding of biology.” The protein folding problem, previously considered among the hardest in biology, became easy for a large number of cases. Isn't anything sacred anymore like the sacred folding of proteins you know made in the image of God. Biological computers use biologically derived molecules — such as DNA and/or proteins — to perform digital or real computations.(Viral vectors) That achievement was made possible by data, in this case the 200,000 protein structures deposited in the Protein Data Bank. The PDB was not assembled with AI in mind. Going forward, many large new biological datasets will be.
The Ginkgo-Google partnership represents there conviction that AI tools and biological data should be developed in tandem. The development of biocomputers has been made possible by the expanding new science of nanobiotechnology. From: Therapeutic applications of nanobiotechnology https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-01909-z/figures/2 nanobiotechnology
https://pubmed.ncbi.nlm.nih.gov/?term=nanobiotechnology
https://patents.justia.com/search?q=nanobiotechnology in
Biological data will not be a passive resource that data scientists process to generate insights. Biological data will be designed and structured to provide maximum insights to AI tools, often with AI design algorithms directly in the loop. It will be necessary to closely integrate the design of the foundry, where data is generated, with the design of the algorithms targeted to particular biological problems. Ginkgo’s strategy for making biology easier to engineer in the AI era could be summarized with three words: “Data is Queen.” https://www.ginkgobioworks.com/2023/08/29/google-and-ginkgo-foundry-scale-data-meets-ai/
”ponsive biomimetic solid lipid nanoparticles for antibiotic delivery against hyaluronidase-secreting bacteria
https://www.sciencedirect.com/science/article/abs/pii/S0378517323003873 hhhhj
New biocomputing method uses enzymes as catalysts for DNA-based molecular computing
Through the use of biological molecules such as DNA or proteins, biocomputing has .... well I'll let you fill in the blink on that thought....
Biocomputing is typically done either with live cells or with non-living, enzyme-free molecules. Biocomputing is typically done either with live cells or with non-living, enzyme-free molecules. Live cells can feed themselves and can heal, but it can be difficult to redirect cells from their ordinary functions toward computation. Non-living molecules solve some of the problems of live cells, but have weak output signals and are difficult to fine-tune and regulate. https://phys.org/news/2023-05-biocomputing-method-enzymes-catalysts-dna-based.html Researchers have developed biological computers using bacteria as part of synthetic biology, which aims to program cells like computers. These computers can solve complex mathematical problems and computational tasks by dividing functions into smaller modules and integrating them through communication between populations
A CRISPR/Cas9-based central processing unit to program complex logic computation in human cells
By enabling rational programming of mammalian cell behavior, synthetic biology is driving innovation across biomedical applications. Using Cas9-variants as core as protein-based central processing units (CPUs) that control gene expression in response to single-guide RNAs as genetic software, we have programmed scalable Boolean logic computations such as the half adder in single human cells. Combining orthogonal Cas9-variants enabled the design of multicore genetic CPUs that provide parallel arithmetic computations. The Cas9-based multicore CPU design may provide opportunities in single-cell mammalian biocomputing to provide biomedical applications https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462112/
A biosynthetic dual-core cell computer
Researchers have integrated two CRISPR-Cas9-based core processors into human cells. This represents a huge step towards creating powerful biocomputers. https://www.sciencedaily.com/releases/2019/04/190416081416.htm#:~:text=Researchers%20have%20integrated%20two%20CRISPR,primary%20objectives%20of%20synthetic%20biology. ISO 10993-7:2008 specifies allowable limits for residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) in individual EO-sterilized medical devices, procedures for the measurement of EO and ECH, and methods for determining compliance so that devices may be released ISO 10993.7-2008 (Biological evaluation of medical devices) and Chinese National Standards, are reference guidelines setting limits for ethylene oxide and 2-chloroethanol in a variety of different materials. In particular, the residual limit for ethylene oxide on face masks is set to 10 µg/g
Mark 8:36 in the Bible states, "For what does it profit a man to gain the whole world and forfeit his soul?". In this verse, Jesus criticizes people's desire for the world and the Pharisees for trying to earn the world's approval by twisting God's worshiping activities. Jesus also says that earthly riches can create a barrier between those who want to follow Christ and the kingdom of God .....
6831